form_8-k.htm
UNITED STATES SECURITIES AND EXCHANGE
COMMISSION
Washington,
DC 20549
_______________
Form 8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of
report (date of earliest event reported):
April
30, 2008
SCOLR
Pharma, Inc.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware
|
|
001-31982
|
|
91-1689591
|
|
(State
or other jurisdiction of incorporation)
|
|
(Commission
File No.)
|
|
(I.R.S.
Employer Identification No.)
|
3625
132nd Avenue SE, Suite 400
Bellevue,
WA 98006
(Address
of principal executive offices)
(425) 373-0171
(Registrant’s
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
As
used in this current report on Form 8-K, unless the context otherwise requires,
the terms “we,” “us,” “the Company,” and “SCOLR Pharma” refer to SCOLR Pharma,
Inc., a Delaware corporation.
Item
1.02. Termination of a Material Definitive Agreement.
On April
30, 2008, we entered into a Lease Termination and Surrender Agreement providing
for termination of our lease agreement with Newport Corporate Center, LLC with
respect to our principal corporate offices in Bellevue, Washington in exchange
for aggregate payments from the landlord of $4.1 million. Under the terms of the
agreement, Newport Corporate Center paid us $1.0 million upon execution of the
agreement and agreed to pay the remaining $3.1 million when we vacate the
premises. The agreement requires us to vacate and surrender the
premises by October 31, 2008.
Item 2.02
Results of Operations and Financial Condition.
On May 2,
2008, SCOLR Pharma, Inc. announced its financial results for the three months
ended March 31, 2008. A copy of the press release containing the announcement is
attached to this current report as Exhibit 99.2.
Item
9.01 Financial Statements and Exhibits.
|
Exhibit No.
|
Description
|
|
99.1
|
SCOLR
Pharma, Inc. press release, dated April 30, 2008.
|
|
99.2
|
SCOLR
Pharma, Inc. press release, dated May 2, 2008.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
SCOLR
PHARMA, INC.
|
|
Dated: May
2, 2008
|
By:
|
/s/
Daniel O. Wilds
|
|
|
|
Daniel
O. Wilds
President
and Chief Executive Officer
|